semaglutide cardiovascular outcomes new study news Semaglutide improved all outcome measures in patients with heart failure - Tirzepatide Oral semaglutide lowers heart failure events Semaglutide Cardiovascular Outcomes: New Study News and Implications

Tirzepatide vssemaglutide Recent research is shedding significant light on the cardiovascular benefits of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.GLP-1 drugs: New eyesight warning for Ozempic/Wegovy - The BMJ A growing body of evidence, including findings from pivotal studies like the SELECT trial, suggests that semaglutide can substantially improve cardiovascular health outcomes in a range of patient populations. This new study news highlights the drug's potential to reduce major adverse cardiovascular events (MACE), an important consideration for patients with obesity and those at high cardiovascular risk.

The SELECT trial, a large-scale clinical investigation, has been instrumental in demonstrating that semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity, even in the absence of diabetes. This finding is particularly noteworthy as it expands the therapeutic role of semaglutide beyond its established efficacy in glycemic control. The study found that semaglutide improved cardiovascular outcomes independently of weight loss, suggesting a direct physiological effect on the cardiovascular system. This is further supported by analyses indicating that semaglutide was associated with a 28% reduction in major adverse cardiac events, with a 12.3% event rate in the placebo group.

Beyond the SELECT trial, other research has explored the impact of different formulations and patient demographics2025年5月15日—Oral semaglutide up to a dose of 14 mg demonstrated a 14% reduction in major adverse cardiovascular events in people aged 50 years or older .... For instance, findings have shown that oral semaglutide reduced major adverse cardiovascular event outcomes in a similar fashion to its injectable counterpart. One notable study reported that oral semaglutide decreased the risk of major cardiovascular events by 14% compared to placebo, with observed reductions across various age and gender groups. Furthermore, semaglutide use was linked to a 45% reduction in a broader composite outcome that included hospitalizations for heart failure.Semaglutide and cardiovascular outcomes in patients with ... This demonstrates a comprehensive cardiovascular protective effectGLP-1 drugs combined with healthy lifestyle habits linked ....

The positive cardiovascular effects of semaglutide are not limited to preventing initial events.2025年4月4日—Additionally,semaglutide use was linked to a 45% reduction in a broader composite outcomethat also included hospitalizations for heart failure ... Research indicates that semaglutide improved all outcome measures in patients with heart failure who were randomized to receive the drug compared to those without heart failure.作者：J Deanfield·2025·被引用次数：26—The SELECT trial foundsemaglutide reduced major adverse cardiovascular events(MACE) in patients with overweight or obesity with ... Additionally, oral semaglutide lowers heart failure events in individuals with type 2 diabetes and pre-existing heart failure, without elevating adverse events. This is a crucial development for a patient group with a high burden of cardiovascular disease.

The implications for clinical practice are significant.作者：AM Lincoff·2023·被引用次数：2593—Whethersemaglutide can reduce cardiovascular riskassociated with overweight and obesity in the absence of diabetes is unknown. Methods: In a ... The FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, marking a milestone in the drug's journey beyond diabetes management.16小时前—Thestudyalso found that healthy habits and GLP-1 RA usage independently benefited heart health. Those who adhered to all eight healthy habits ... This approval is based on robust data demonstrating its efficacy in mitigating cardiovascular risks.

When considering semaglutide's role, it's important to compare it with other emerging treatments.Study Finds Oral Semaglutide Vastly Reduces Heart ... While tirzepatide has also shown promising cardiovascular benefits, some studies suggest that tirzepatide was associated with significantly lower risks of major adverse cardiovascular events and all-cause mortality compared to semaglutide.Study Finds Oral Semaglutide Vastly Reduces Heart ... However, other real-world data points indicate that semaglutide significantly reduced the risk of heart attack, stroke, and death compared to tirzepatide in patients with obesity. The ongoing evaluation of these GLP-1 receptor agonists and other related medications, like tirzepatide, continues to refine our understanding of their comparative cardiovascular impact.

It is also worth noting that the combination of GLP-1 drugs combined with healthy lifestyle habits appears to offer synergistic benefitsSemaglutide and Cardiovascular Outcomes in Obesity .... A study found that adherence to eight healthy habits independently benefited heart health, and this benefit was further amplified when combined with GLP-1 RA usage. This underscores the importance of a holistic approach to cardiovascular healthFDA approves Novo Nordisk's oral semaglutide for ....

The efficacy of semaglutide in reducing cardiovascular risk is observed across different patient profilesSemaglutide shown to improve cardiovascular outcomes .... For example, semaglutide lowers cardiovascular risk in T2DM, primarily by improving major adverse cardiovascular events like nonfatal myocardial infarction. Moreover, semaglutide can reduce cardiovascular risk associated with overweight and obesity, even in the absence of diabetes. The Semaglutide Cardiovascular Outcomes Trial (SOUL) was specifically designed to assess the cardiovascular efficacy of oral semaglutide in persons with established cardiovascular disease and at least one risk factor for type 2 diabetes.

In conclusion, the latest news surrounding semaglutide cardiovascular outcomes paints a picture of a drug with significant potential to impact cardiovascular health. From reducing major adverse cardiovascular events and heart failure events to demonstrating direct cardiovascular benefits independent of weight loss, the evidence is mounting. As further studies are conducted, including those looking at the comparative effectiveness with tirzepatide, the role of semaglutide in comprehensive cardiovascular care is set to expand.